HIV medications lopinavir and ritonavir (LPVR), in combination, are currently being investigated as a proposed COVID-19 treatment. The potential mechanism of action of LPVR is that it may disrupt the replication and spread of the severe acute respiratory syndrome coronavirus 2 — or SARS-CoV-2 — within the body. However, there is uncertainty around the clinical effectiveness of LPVR in patients with COVID-19. CADTH reviewed and summarized the evidence regarding the clinical effectiveness of lopinavir-ritonavir for the treatment and prevention of COVID-19.
Link to Report
Was this site helpful?
If you couldn’t find what you are looking for, please submit a request.